GLG News by Physicians who Implant Intraocular Lenses

Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small...

Genentech is aiming to curb the off-label use of Avastin in favor of its blockbluster AMD drug Lucentis (which costs 50x more!).  These attempts will make it more difficult to prescribe Avastin and help them boost sales of Lucentis in the short term.  However, in the long term, Genentech is...

ALTY-0501 is new medication being used in the Dry Eye Market.  This reports reveals positive results from a Phase 2 Study.  It is exciting as there are limited products for treating Dry Eye; and this could be a new rival from Restatisis (Allergan; AGN).

An extensive meta-analysis by Wong et al involving a 149,203 patients shows that antioxidants do not prevent early macular degeneration (the formation of drusen.)  However, it does not refute the role of antioxidants in preventing wet or advanced macular degeneration (AMD). ...

Genetech (DNA) is looking to curb the off label use of its oncology medications (Avastin) in order to boost Lucentis sales.  It is a terrible PR move for the company that exposes its greed and bumbling moves but a good fianancial decision to maximize its profits for Lucentis. 

       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...

Omega-3 supplementation could be a useful strategy for protecting against retinopathy of prematurity (ROP), say Swedish investigators. In the study, mice with retinopathy were fed food enriched with either omega-3 or omega-6. Mice that ate omega-3 initially lost fewer retinal blood vessels than mice...

Patients with high arterial pulse pressure may be at increased risk for high-tension open angle glaucoma, a Dutch study concludes. Researchers analyzed data from 5,317 individuals, 215 of who had definite or probable open-angle glaucoma and 5,102 of whom were disease free.The analysis found that high-tension...

Alcon holds more than 70% of Wavelights shares and its takeover of Wavelight has been approved by the German authorities. WHile wavelight produces some interesting intraocular lenses, it is clear that Alcons interest in Wavelight lies in its realiable and fast excimer laser system that can be used for...

New research indicating the presence of amyloid-beta protein in dying retinal cells  suggests a new direction in glaucoma research. Amyloid-beta is a protein found in Alzheimer's plaques. Using a rat model of glaucoma, the researchers found that the dying retinal cells showed accumulation of amyloid-beta....